Related Experiment Video

Updated: May 10, 2026

Fetal Mouse Cardiovascular Imaging Using a High-frequency Ultrasound (30/45MHZ) System
07:34

Fetal Mouse Cardiovascular Imaging Using a High-frequency Ultrasound (30/45MHZ) System

Published on: May 5, 2018

Pharmacogenomics and heart failure in congenital heart disease

Simon de Denus1, Paul F Kantor

  • 1Faculty of Pharmacy, Université de Montréal, Montreal Heart Institute, Montreal, Québec, Canada.

The Canadian Journal of Cardiology
|June 25, 2013
PubMed

Insights

Congenital heart disease (CHD) management requires personalized treatment due to genomic variability. Pharmacogenomics offers a path to tailor heart failure therapies for better outcomes in CHD patients.

Area of Science:

  • Cardiology
  • Genomics
  • Pharmacology

Background:

  • Congenital heart disease (CHD) presents lifelong heart failure management challenges.
  • Current therapies often extrapolate from adult left ventricular failure, overlooking CHD-specific genomic factors.
  • Genomic variability in CHD suggests a need for individualized treatment approaches.

Purpose of the Study:

  • To explore the potential of pharmacogenomics in managing congenital heart disease (CHD) and heart failure.
  • To highlight the benefits of individualizing drug therapy based on genomic data for CHD patients.
  • To assess the feasibility of predicting treatment response using genomic information in CHD management.

Main Methods:

  • Review of current therapeutic principles in CHD heart failure.
  • Analysis of evidence for genomic variability in CHD etiology and progression.
  • Exploration of pharmacogenomic data and its application in treatment algorithms.

Main Results:

  • Genomic variability is evident in the origin and progression of CHD.
  • Pharmacogenomics offers a promising avenue for personalized CHD management.
  • Individualized drug therapy and prediction of treatment response may be achievable through genomic integration.

Conclusions:

  • Personalized pharmacogenomic approaches are crucial for optimizing heart failure management in CHD.
  • Integrating genomic data into treatment algorithms can enhance therapeutic efficacy and patient outcomes.
  • Future research should focus on developing and validating pharmacogenomic strategies for CHD.

More Related Videos

Analysis of Congenital Heart Defects in Mouse Embryos Using Qualitative and Quantitative Histological Methods08:28

Analysis of Congenital Heart Defects in Mouse Embryos Using Qualitative and Quantitative Histological Methods

Published on: March 10, 2020

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...